IGF-1 LR3 1mg

IGF-1 LR3 1mg: Research Overview

Insulin-like Growth Factor-1 Long R3 (IGF-1 LR3) is a recombinant analog of native IGF-1 engineered for enhanced stability and potency in laboratory research settings. This 83-amino-acid variant features a glutamate-to-arginine substitution at position 3 of the mature IGF-1 sequence combined with a 13-amino-acid N-terminal extension peptide, yielding a molecule with markedly reduced affinity for IGF-binding proteins (IGFBPs) and an extended biological half-life in vitro. BioSim Peptides supplies IGF-1 LR3 as a lyophilized powder at 1mg per vial, verified to ≥98% purity by HPLC and mass spectrometry, for use exclusively in controlled laboratory research investigating growth factor signaling, myogenesis, and tissue regeneration pathways.

Native IGF-1 is the primary mediator of growth hormone’s anabolic effects in skeletal muscle and other tissues, acting through the IGF-1 receptor (IGF-1R) to activate the PI3K/AKT and Ras/MAPK signaling cascades. However, native IGF-1 is rapidly sequestered in vivo by six high-affinity IGFBPs that limit its bioavailability to approximately 1% of the total circulating pool. IGF-1 LR3 was specifically designed to overcome this limitation: the combined Arg³ substitution and N-terminal extension reduce IGFBP binding affinity by over 100-fold while preserving full agonist activity at the IGF-1R, making this analog a powerful tool for researchers studying growth factor biology without the confounding influence of endogenous binding proteins¹².

Molecular Background & Mechanism of Action

IGF-1 LR3 engages the type 1 IGF receptor (IGF-1R), a heterotetrameric transmembrane tyrosine kinase, with affinity comparable to wild-type IGF-1. Ligand binding induces receptor autophosphorylation at tyrosine residues within the intracellular kinase domain, creating docking sites for insulin receptor substrate (IRS) proteins and Shc adaptor proteins. IRS-1/2 phosphorylation recruits the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), which generates phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) at the plasma membrane, leading to membrane recruitment and phosphorylation of AKT (PKB). Activated AKT phosphorylates downstream targets including mTORC1, FoxO transcription factors, and GSK-3β, collectively promoting protein synthesis, inhibiting proteolysis, and driving cell cycle progression²³.

The critical structural feature of IGF-1 LR3 is its resistance to IGFBP-mediated neutralization. Crystallographic and mutagenesis studies have established that the N-terminal region of native IGF-1 (residues 1-3) forms essential contacts with IGFBP-3 and IGFBP-5. The Glu³→Arg substitution in LR3 introduces both a charge reversal and a steric clash with the IGFBP binding cleft, while the 13-residue N-terminal extension peptide derived from porcine growth hormone further obstructs the IGFBP interaction surface. The result is a molecule that remains freely diffusible in culture media and tissue preparations, providing sustained IGF-1R activation that more closely models continuous receptor stimulation¹⁴.

Additionally, IGF-1 LR3 retains cross-reactivity with the insulin receptor (IR) and IGF-1R/IR hybrid receptors, though with approximately 10-fold lower affinity than at the cognate IGF-1R. Researchers should account for this pharmacological overlap when interpreting results in cell types co-expressing both receptor families. The extended half-life of LR3 — estimated at 20-30 hours in most experimental systems compared to 10-20 minutes for native IGF-1 — enables convenient once-daily dosing protocols in longitudinal cell culture and tissue explant studies¹⁵.

Preclinical & Clinical Evidence

The biological activity of Long R3 IGF-1 in myogenic systems has been extensively characterized. Xi et al. (2004) demonstrated that Long-R3-IGF-I dose-dependently stimulated both proliferation and differentiation of L6 rat myogenic cells, and critically, that co-administration of recombinant IGFBP-3 inhibited wild-type IGF-I activity but failed to suppress Long-R3-IGF-I-mediated responses, confirming the analog’s functional resistance to binding protein antagonism². In a complementary study using porcine embryonic myoblast cultures, Pampusch et al. (2005) showed that IGFBP-5 was equally ineffective at blocking Long-R3-IGF-I-stimulated myoblast proliferation, while it potently suppressed native IGF-I activity³.

Early in vivo metabolic studies established the translational relevance of the LR3 modification. Hill et al. (1999) administered Long(R3)-IGF-1 to beef heifers and documented significant reductions in plasma amino acid concentrations and urea nitrogen, consistent with increased whole-body protein synthesis and reduced amino acid oxidation — effects that were substantially more pronounced and sustained compared to equivalent doses of native IGF-1¹. In a landmark 2010 analytical study, Kohler et al. developed a mass spectrometry method for detecting His-tagged Long-R³-IGF-I and unequivocally identified the analog in confiscated products, establishing that LR3 migrates with a distinct mass shift consistent with the N-terminal extension and confirming its structural identity as a discrete molecular entity⁴.

Contemporary applications highlight the versatility of IGF-1 LR3 as a research tool. Lu et al. (2023) reported successful recombinant expression of LR3 IGF-1 fused with xylanase in Pichia pastoris, achieving high-yield soluble production suitable for large-scale experimental use and demonstrating that the LR3 modification is compatible with fusion protein strategies⁵. Most recently, Yavuz et al. (2025) incorporated controlled-release IGF-1 LR3 into a decellularized plant-stem-based nerve conduit and demonstrated significantly enhanced sciatic nerve regeneration in a rat model, with improved axonal alignment, myelination, and functional recovery compared to conduits without growth factor supplementation — a compelling illustration of LR3’s utility in complex tissue engineering applications⁷. In a complementary study examining growth-restricted fetal physiology, White et al. (2025) administered IGF-1 LR3 to late-gestation growth-restricted fetal sheep and found that while the analog did not reverse established growth restriction, it provided important negative data clarifying the temporal limitations of IGF-1R-targeted interventions in developmental contexts, underscoring the importance of treatment timing in experimental design⁸.

Research Applications

• Skeletal Muscle Myogenesis: Investigate the role of sustained IGF-1R signaling in myoblast proliferation, differentiation, and fusion using C2C12 or L6 myogenic cell lines. IGF-1 LR3’s IGFBP resistance enables researchers to study growth factor effects without interference from endogenously secreted binding proteins²³.
• Satellite Cell Biology: Examine the effects of prolonged IGF-1 exposure on muscle satellite cell activation, self-renewal, and commitment to the myogenic lineage in primary cell cultures and isolated fiber preparations.
• PI3K/AKT/mTOR Pathway Studies: Utilize IGF-1 LR3 as a potent and sustained activator of the PI3K/AKT signaling axis to dissect downstream phosphorylation cascades, including mTORC1-mediated protein synthesis, FoxO-regulated proteolysis, and GSK-3β-mediated metabolic control.
• Tissue Engineering & Regenerative Medicine: Incorporate IGF-1 LR3 into biomaterial scaffolds, hydrogels, or controlled-release systems to evaluate its effects on cell survival, proliferation, and tissue remodeling in three-dimensional culture models⁷.
• Comparative Growth Factor Signaling: Compare the signaling kinetics, receptor trafficking, and transcriptional outputs of IGF-1 LR3 versus native IGF-1, insulin, and mechano-growth factor (MGF) to dissect ligand-specific versus shared signaling nodes.
• Protein Metabolism Research: Model the effects of sustained IGF-1 tone on protein synthesis and degradation rates using isotopic tracer methodologies in cell and tissue culture systems¹.

Comparative Context

Researchers evaluating growth factor tools for myogenesis and tissue regeneration studies often weigh IGF-1 LR3 against native IGF-1, mechano-growth factor (MGF), and IGF-1 DES (1-3). The table below summarizes key differentiating features relevant to experimental design. IGF-1 LR3’s most distinctive advantage is its near-complete resistance to IGFBP sequestration, which translates to markedly prolonged signaling duration and reduced experimental variability from culture-condition-dependent IGFBP expression. MGF (IGF-1Ec) preferentially activates satellite cell proliferation through a somewhat distinct receptor interaction profile, while IGF-1 DES (a truncated IGF-1 lacking the N-terminal tripeptide) exhibits intermediate IGFBP affinity and a shorter half-life than LR3. For experiments requiring sustained, high-amplitude IGF-1R activation in serum-containing media or complex co-culture systems where endogenous IGFBPs are present, IGF-1 LR3 represents the research tool of choice²³⁶.

Safety & Laboratory Handling

Store lyophilized IGF-1 LR3 at -20°C protected from light and moisture. For reconstitution, use sterile bacteriostatic water or dilute acetic acid (10-20 mM) — the peptide exhibits optimal solubility under mildly acidic conditions (pH 3-4). Do not use saline or neutral phosphate buffers for initial reconstitution, as IGF-1 LR3 may precipitate near physiological pH. Reconstituted stock solutions should be aliquoted, stored at 2-8°C, and used within 30 days. For long-term storage, aliquot and freeze at -20°C or -80°C. Avoid repeated freeze-thaw cycles, which promote aggregation and loss of bioactivity. Use appropriate personal protective equipment (PPE) including gloves, lab coat, and eye protection. Work in a certified biosafety cabinet when preparing sterile solutions. This product is for laboratory research use only — not for diagnostic or therapeutic applications. Not for human or veterinary use.

References

1. Hill RA, Hunter RA, Lindsay DB, Owens PC. “Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.” Domest Anim Endocrinol. 1999 May;16(4):219-229. PMID: 10370861.
2. Xi G, Kamanga-Sollo E, Pampusch MS, White ME, Hathaway MR, Dayton WR. “Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells.” J Cell Physiol. 2004 Sep;200(3):387-394. PMID: 15254966.
3. Pampusch MS, Xi G, Kamanga-Sollo E, Loseth KJ, Hathaway MR, Dayton WR. “Production of recombinant porcine IGF-binding protein-5 and its effect on proliferation of porcine embryonic myoblast cultures in the presence and absence of IGF-I and Long-R3-IGF-I.” J Endocrinol. 2005 Apr;185(1):197-206. PMID: 15817840.
4. Kohler M, Thomas A, Walpurgis K, Terlouw K, Schänzer W, Thevis M. “Detection of His-tagged Long-R³-IGF-I in a black market product.” Growth Horm IGF Res. 2010 Oct;20(5):386-390. PMID: 20675162.
5. Lu Z, Liu N, Huang H, Wang Y, Tu T, He Y. “Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.” Appl Microbiol Biotechnol. 2023 Jul;107(14):4495-4509. PMID: 37261455.
6. Engel MG, Narayan S, Cui MH, Branch CA, Zhang X, de la Monte SM. “Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.” J Alzheimers Dis. 2025 Jan;103(2):351-364. PMID: 39610283.
7. Yavuz E, Sağır MS, Ercan A, Erginer M, Barlas FB, Güner FS, Köse GT. “Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.” Int J Biol Macromol. 2025 Nov;297:147888. PMID: 41015370.
8. White A, Stremming J, Wesolowski SR, Al-Juboori SI, Dobrinskikh E, Brown LD. “IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.” Am J Physiol Endocrinol Metab. 2025 Jan 1;328(1):E21-E32. PMID: 39679943.